Why Is Summit Therapeutics Stock Trading Higher On Monday?

1. Akeso's ivonescimab received NMPA approval for a second indication in China. 2. Summit stock dropped nearly 30% after the announcement. 3. HARMONi-2 trial showed significant progression-free survival advantage for ivonescimab. 4. Summit is enrolling patients in HARMONi-7 trial with registrational intent. 5. BioNTech's stock gained following positive news related to ivonescimab's performance.